{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T18:57:25Z","timestamp":1780772245966,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ygyno.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:41:31Z","timestamp":1748346091000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma"],"prefix":"10.1016","volume":"198","author":[{"given":"Yasushi","family":"Iida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Churchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Croy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gentleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzyvia","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Nirsimloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Simon","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2025.05.016_bb0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ijgc-2020-001656","article-title":"Clear cell carcinoma of the ovary: a clinical and molecular perspective","volume":"31","author":"Iida","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.016_bb0010","doi-asserted-by":"crossref","first-page":"18797","DOI":"10.1038\/s41598-024-69796-4","article-title":"Integrated genomic\/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin","volume":"14","author":"Nishijima","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.016_bb0015","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1186\/s12885-024-13125-5","article-title":"Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma","volume":"24","author":"Chao","year":"2024","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.ygyno.2025.05.016_bb0020","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-21-3817","article-title":"Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes","volume":"28","author":"Bolton","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ygyno.2025.05.016_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205242","article-title":"Genomic sub-classification of ovarian clear cell carcinoma revealed by distinct mutational signatures","volume":"13","author":"Oliveira","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ygyno.2025.05.016_bb0030","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.ajpath.2017.06.012","article-title":"Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks","volume":"187","author":"Murakami","year":"2017","journal-title":"Am J Pathol"},{"issue":"6001","key":"10.1016\/j.ygyno.2025.05.016_bb0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.016_bb0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12885-024-13389-x","article-title":"Molecular subtype of ovarian clear cell carcinoma: an analysis of 80 Chinese patients using the TCGA molecular classification of endometrial cancer","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2025.05.016_bb0045","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.ygyno.2025.05.016_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2017.417","article-title":"HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer","volume":"118","author":"Barnes","year":"2018","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.ygyno.2025.05.016_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215332","article-title":"Tumor-infiltrating lymphocytes (TILs) in epithelial ovarian cancer: heterogeneity, prognostic impact, and relationship with immune checkpoints","volume":"14","author":"Hudry","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ygyno.2025.05.016_bb0060","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1136\/ijgc-2024-005662","article-title":"Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancer","volume":"34","author":"Woo","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2025.05.016_bb0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10147-007-0670-1","article-title":"Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis","volume":"12","author":"Takano","year":"2007","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ygyno.2025.05.016_bb0070","series-title":"Female Genital Tumours","article-title":"World Health Organisation classification of tumours","author":"board, W.c.e","year":"2020"},{"issue":"7","key":"10.1016\/j.ygyno.2025.05.016_bb0075","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/PAS.0b013e318164edf7","article-title":"Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases","volume":"32","author":"Han","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ygyno.2025.05.016_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PGP.0b013e318273fd07","article-title":"HNF-1beta in ovarian carcinomas with serous and clear cell change","volume":"32","author":"DeLair","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2025.05.016_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114205","article-title":"Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas","volume":"208","author":"Southworth","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.016_bb0090","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","article-title":"Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome","volume":"11","author":"Hollis","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ygyno.2025.05.016_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","article-title":"DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal","year":"2016","journal-title":"Genome Biol"},{"issue":"11","key":"10.1016\/j.ygyno.2025.05.016_bb0100","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.016_bb0105","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ygyno.2025.05.016_bb0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1042\/ETLS20170142","article-title":"The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy","volume":"1","author":"Bedognetti","year":"2017","journal-title":"Emerg Top Life Sci"},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.016_bb0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.016_bb0120","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1038\/s41598-025-89270-z","article-title":"Infiltration of CD8(+) cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ygyno.2025.05.016_bb0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial","author":"Kristeleit","year":"2025","journal-title":"JAMA, Oncol11(4)"},{"issue":"4","key":"10.1016\/j.ygyno.2025.05.016_bb0130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/path.5849","article-title":"Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas","volume":"256","author":"Heinze","year":"2022","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.ygyno.2025.05.016_bb0135","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00262-022-03326-x","article-title":"Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy","volume":"72","author":"Gu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.ygyno.2025.05.016_bb0140","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21873\/cgp.20460","article-title":"Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes","volume":"21","author":"Tsunematsu","year":"2024","journal-title":"Cancer Genomics Proteomics"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:43:47Z","timestamp":1762231427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"alternative-id":["S0090825825008479"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.05.016","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.03.20.644313","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}